September 19, 2008 – Last month, MIV announced continued positive results for VESTAsync, a polymer-free drug-eluting stent, at a twelve-month clinical follow-up for fifteen patients in its first-in-man VESTASYNC I Trial, reporting that all patients remain free of any major adverse cardiac events or MACE.
MIV also announced that it now has accumulated nine-month intravascular ultrasound (IVUS) and Quantitative Coronary Angiography (QCA) for these same patients. This data showed no statistical difference from the safety and efficacy data reported at four months.
